Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by G. Grizzi
P2.04-12 a Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.04-11 an IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients With NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Panel of 12-lncRNA Signature Predicts Survival of Pancreatic Adenocarcinoma
Journal of Cancer
Oncology
MA11.03 Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy After Nivolumab in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-84 High Basal Serum EGF Levels Predicts Response to CIMAvax-EGF, a Therapeutic Vaccine for Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary